Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Realty & banking stocks, major losers
Tue, 16 Jul 01:30 pm

Due to persistent weakness in index heavy-weights Indian share markets continued to trade deep in the red in the post-noon trading session. Majority of the sectoral indices are trading in the red with realty, banking and capital goods stocks being the biggest losers. However, FMCG, oil and gas and IT stocks are among the few stocks trading in the green.

BSE-Sensex is down 244 points and NSE-Nifty is trading 86 points down. BSE Mid Cap is trading down 1.2% and BSE Small Cap index is trading down by 0.8%. The rupee is trading at 59.4 to the US dollar.

Energy stocks are trading mixed with Oil & Natural Gas Corporation (ONGC) and Bharat Petroleum Corporation Ltd (BPCL) being the biggest gainers while Jindal Drill and Mangalore Refineries & Petrochemicals Ltd (MRPL) are the biggest losers. As per a leading financial daily, Reliance Industries Ltd (RIL) is no longer interested in the gas distribution business. Reliance Gas had won bids for city gas distribution for three cities namely Rajahmundry in Andhra Pradesh, Shahdol in Madhya Pradesh and Yanam in Pondicherry in 2009 during the second round of bidding. However, as per Petroleum and Natural Gas Regulatory Board (PNGRB), RIL has said that it is no longer interested in laying pipelines in these cities. Reportedly distribution in these three cities may be put up on auction again. In February, PNGRB had issued licences for piped natural gas in six cities. RIL stock is currently trading down by 0.3%.

Domestic pharma stocks are trading mixed with Indoco Remdies and Biocon being the leading gainers and Dishman Pharma and Aurobindo Pharma being the biggest losers. Glenmark recently confirmed its Para IV challenge for drug Vimpat brand (generically known as Lacosamide tablets) in US. The company has filed an ANDA (Abbreviated New Drug Application) with Para IV for both tablets and oral solution. The drug is indicated as adjunctive therapy for the treatment for epilepsy. UCB is the innovator of the drug. Reportedly, on back of the Para IV filing, the innovator has sued Glenmark in the district court of Delaware to prevent Glenmark from early launch of drug before the patent expiry in March 2022. Annual sales of Vimpat brand in the US stand at around US$ 353 m. If Glenmark is successful in its patent challenge then it will have a fair chance of availing the 180-days exclusivity. Glenmark is trading up by 0.5%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Realty & banking stocks, major losers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.